Synonyms: AMG 423 | AMG-423 | CK-1827452
Compound class:
Synthetic organic
Comment: Omecamtiv mecarbil is an investigational small molecule which is a direct activator of cardiac myosin [3]. This compound is being investigated as a novel therapy for patients with chronic heart failure due to systolic dysfunction. Results from the first-in-man study are reported by Teerlink et al. (2011) [4].
Omecamtiv mecarbil is claimed in patent US7507735 B2 [2]. |
|
References |
1. Cleland JG, Teerlink JR, Senior R, Nifontov EM, Mc Murray JJ, Lang CC, Tsyrlin VA, Greenberg BH, Mayet J, Francis DP et al.. (2011)
The effects of the cardiac myosin activator, omecamtiv mecarbil, on cardiac function in systolic heart failure: a double-blind, placebo-controlled, crossover, dose-ranging phase 2 trial. Lancet, 378 (9792): 676-83. [PMID:21856481] |
2. Morgan BP, Muci A, Lu P-P, Kraynack EA, Tochimoto T, Morgans DJ Jr. (2009)
Compounds, compositions and methods. Patent number: US7507735 B2. Assignee: Cytokinetics, Inc.. Priority date: 17/06/2004. Publication date: 24/03/2009. |
3. Morgan BP, Muci A, Lu PP, Qian X, Tochimoto T, Smith WW, Garard M, Kraynack E, Collibee S, Suehiro I et al.. (2010)
Discovery of omecamtiv mecarbil the first, selective, small molecule activator of cardiac Myosin. ACS Med Chem Lett, 1 (9): 472-7. [PMID:24900233] |
4. Teerlink JR, Clarke CP, Saikali KG, Lee JH, Chen MM, Escandon RD, Elliott L, Bee R, Habibzadeh MR, Goldman JH et al.. (2011)
Dose-dependent augmentation of cardiac systolic function with the selective cardiac myosin activator, omecamtiv mecarbil: a first-in-man study. Lancet, 378 (9792): 667-75. [PMID:21856480] |
5. Teerlink JR, Diaz R, Felker GM, McMurray JJV, Metra M, Solomon SD, Adams KF, Anand I, Arias-Mendoza A, Biering-Sørensen T et al.. (2020)
Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction: GALACTIC-HF baseline characteristics and comparison with contemporary clinical trials. Eur J Heart Fail, 22 (11): 2160-2171. [PMID:32985088] |
6. Teerlink JR, Diaz R, Felker GM, McMurray JJV, Metra M, Solomon SD, Legg JC, Büchele G, Varin C, Kurtz CE et al.. (2020)
Omecamtiv Mecarbil in Chronic Heart Failure With Reduced Ejection Fraction: Rationale and Design of GALACTIC-HF. JACC Heart Fail, 8 (4): 329-340. [PMID:32035892] |